| Japanese |
|---|
| Title | 15- (p-ヨードフェニル) -3 (R, S) -メチルペンタデカン酸 (123I) 注射液の血液中および尿中代謝物の検討 |
|---|
| Subtitle | 技術報告 |
|---|
| Authors | 岡野栄*, 吉村弘一*, 岡野京子*, 伊藤修*, 倉見美規*, 池窪勝治**, 米倉義晴***, 西村恒彦****, 鳥塚莞爾***** |
|---|
| Authors(kana) | |
|---|
| Organization | *日本メジフィジックス株式会社中央研究所, **神戸市立中央市民病院核医学科, ***京都大学医学部脳病態生理学講座, ****国立循環器病センター放射線診療部, *****福井医科大学 |
|---|
| Journal | 核医学 |
|---|
| Volume | 29 |
|---|
| Number | 12 |
|---|
| Page | 1489-1493 |
|---|
| Year/Month | 1992/12 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」ラットおよびウサギにおける123I-BMIPPの体内動態, 血中および尿中の放射化学的成分の検討を行うとともに第1相臨床試験における健常人の血中および尿中放射化学的成分について検索を加え, 123I-BMIPPの代謝の様相を評価した. 心臓に集積した放射能は経時的に緩徐に減少し, 主な排泄経路は腎臓を経て尿中へ排泄される経路であった. 主な血中の放射化学的成分はいずれも123I-PIPAであることが確認され, 尿中の放射化学的成分としては, 主として123I-PIPAの抱合体であることが確認された. このことから123I-BMIPPは体内においてまずはじめにα酸化され, 次いでβ酸化を受ける経路で代謝され, 123I-PIPAとして血中に放出されると考えられた. 血中の123I-PIPAは, さらに抱合化を受け尿中に排泄されたものと判断された. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 123I-BMIPP, Metabolite, Animal, Human. |
|---|
| English |
|---|
| Title | Metabolite of 15-p-Iodophenyl-3 (R, S) -Pentadecanoic Acid (123I) in Blood and Urine |
|---|
| Subtitle | Technical Reports |
|---|
| Authors | Sakae OKANO*, Hirokatsu YOSHIMURA*, Kyoko OKANO*, Osamu ITOH*, Miki KURAMI*, Katsuji IKEKUBO**, Yoshiharu YONEKURA***, Tsunehiko NISHIMURA****, Kanji TORIZUKA***** |
|---|
| Authors(kana) | |
|---|
| Organization | *Research and Development Division, Nihon Medi-Physics Co., Ltd., **Department of Nuclear Medicine, Kobe City General Hospital, ***Department of Brain Pathophysiology, Kyoto University School of Medicine, ****Department of Radiology, National Cardiovascular Center, *****Fukui Medical School |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 29 |
|---|
| Number | 12 |
|---|
| Page | 1489-1493 |
|---|
| Year/Month | 1992/12 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]We analyzed metabolites of 123I-BMIPP in blood and urine using rats, rabbits and human, while human samples were obtained from normal volunteers of Phase I clinical study. We estimated metabolic pathway of 123I-BMIPP as a myocardial metabolic imaging agent. Radioactivity accumulated in heart after administration gradually decreased and was mainly excreted to bladder via kidneys. The main radioactive component in blood was 123I-PIPA for any species and the urinary components were metabolic conjugates of 123I-PIPA. As results of these studies, we considered that 123I-BMIPP was metabolized to 123I-PIPA by α-oxidation process for the first step, follow by β-oxidation process, then 123I-PIPA was released to blood from tissues. Moreover, 123I-PIPA in blood was conjugated with other compounds and excreted to the bladder. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 123I-BMIPP, Metabolite, Animal, Human. |
|---|